Stem, Inc. Q3 2025 Earnings Recap

VSTM Q3 2025 November 4, 2025

Get alerts when VSTM reports next quarter

Verastem Oncology reported strong Q3 results with net product revenue of $11.2 million from the AVMAPKI FAKZYNJA CO-PACK launch, indicating robust adoption by healthcare providers and effective commercial strategies.

Earnings Per Share Miss

$-1.35 vs $-0.51 est.

-164.7% surprise

Revenue Miss

11242000 vs 16529330 est.

-32.0% surprise

Market Reaction

1-Day -20.1%

5-Day -18.48%

30-Day +7.47%

See VSTM alongside your other holdings

Add to your portfolio — free

Key Takeaways

Net product revenue for Q3 2025 was $11.2 million, exceeding expectations fueled by strong physician engagement and patient initiation.
The company successfully achieved its three launch objectives: enhancing physician outreach, supporting patient access, and streamlining reimbursement processes.
Over 60% of prescriptions are generated by gynecological oncologists, with a substantial presence in both academic and community practices.
Enrollment in clinical trials for AVMAPKI FAKZYNJA CO-PACK and VS-7375 programs remains on track, with positive safety and tolerability data reported.
High engagement levels with healthcare providers and effective outreach to patients showcase the brand's strength and market penetration.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit VSTM on AllInvestView.

Next Q1 2026